Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have ...

The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...